IL13
Interleukin-13
As of the edition of 20 October 2026, IL13 (interleukin-13, UniProt P35225) has 11 drugs tested at it and 14 companies on the list, 4 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P35225
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 13
- Disease areas
- Immune system; Skin and connective tissue; Inherited and neonatal; Lungs and airways; Digestive system; Blood and lymph; Ear, nose and throat; Cancer
- Registered trials of its drugs
- 116
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 3 |
| Went quiet | 4 |
| Stopped | 1 |
| Status not established | 1 |
| Total | 11 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Lebrikizumab | Marketed | Phase 4 | Ends 2036 |
| Tralokinumab | Marketed | Phase 4 | Ends 2033 |
| Cendakimab | Active | Phase 3 | none listed |
| QAX-576 | Stopped | Phase 2 | none listed |
| APG777 | Active | Phase 2 | none listed |
| Anrukinzumab | Went quiet | Phase 2 | none listed |
| Romilkimab | Went quiet | Phase 2 | none listed |
| LY3650150 | Active | Phase 3 | none listed |
| CNTO-5825 | Went quiet | Phase 1 | none listed |
| GSK679586 | Went quiet | Phase 2 | none listed |
| SAR443765 | Status not established | Phase 1 | none listed |
11 of 11 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Route B | 2 |
| Engaged | 5 |
| Undetermined | 3 |
| Total on the list | 14 |
| Company | Route |
|---|---|
| Novartis | Route A |
| Eli Lilly | Route B |
| LEO Pharma | Route B |
The other 11 companies at IL13
In the product14 companies in all; 11 are not named here, and no score is.
See the 14 companies at IL13, ranked, with the facts behind eachRequest access. Nothing is shown until you do.